Literature DB >> 34878873

Racial and Ethnic Disparities in COVID-19 Infection and Hospitalization in the Active Component US Military.

John M Young1, Shauna L Stahlman1, Shawn S Clausen1, Mark L Bova1, James D Mancuso1.   

Abstract

Objectives. To assess COVID-19 disparities in the active component US military with an emphasis on race and ethnicity. Methods. In this retrospective cohort study, we calculated the incidence of COVID-19 testing, infection, and hospitalization in the active component US military in calendar year 2020. Results. Overall, 61.3 per 100 population per year were tested for COVID-19, 10.4% of tests were positive, and 1.1% of infected individuals were hospitalized. Non-Hispanic Blacks and Hispanics had a rate of testing for COVID-19 similar to that of Whites but had a higher risk of infection (adjusted risk ratio [ARR] = 1.25 and 1.26, respectively) and hospitalization (ARR = 1.28 and 1.21, respectively). Conclusions. Although of lower magnitude than seen in civilian populations, racial and ethnic disparities in COVID-19 infection and hospitalizations exist in the US military despite universal eligibility for health care, similar rate of testing, and adjustment for comorbidities and other factors. Simply making health care coverage available may be insufficient to ensure health equity. Interventions to mitigate disparities in the US military should target the patient, provider, health care system, and society at large. (Am J Public Health. 2021;111(12):2194-2201. https://doi.org/10.2105/AJPH.2021.306527).

Entities:  

Mesh:

Year:  2021        PMID: 34878873      PMCID: PMC8667833          DOI: 10.2105/AJPH.2021.306527

Source DB:  PubMed          Journal:  Am J Public Health        ISSN: 0090-0036            Impact factor:   9.308


  1 in total

1.  COVID-19 test positivity by occupation using the Delphi US COVID-19 trends and impact survey, September-November 2020.

Authors:  Jean M Cox-Ganser; Paul K Henneberger; David N Weissman; Garret Guthrie; Caroline P Groth
Journal:  Am J Ind Med       Date:  2022-07-05       Impact factor: 3.079

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.